Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Participants
Cystic Fibrosis - 3 Years to 16 Years (Child)
Interventions
Drug: Cephalexin|Drug: Placebo
Outcome measures
The relative change in LCI2.5 between day 0 and day 14 (relative change = [LCI2.5 at day 14-LCI2.5 at day 0]/LCI2.5 at day 0).|Time to next pulmonary exacerbation|Relative change in percent predicted FEV1 between day 0 and day 14|Absolute change in FEV1 (mL) between day 0 and day 14|Relative change in LCI5 between day 0 and day 14.|Absolute change in LCI2.5 and LCI5 between day 0 and day 14|Absolute change in the CFQ-R(R) between day 0 and day 14.|MSSA airway culture positivity at day 14|Time until next growth of MSSA on clinical microbiology samples|Number of new CF respiratory pathogens (P. aeruginosa etc) from clinical respiratory samples
Related topics
Antibiotic treatment for stenotrophomonas maltophilia in people with cystic fibrosis
Antibiotic treatment of early pseudomonas aeruginosa
Antibiotics for pulmonary exacerbations
Inhaled antibiotics in cystic fibrosis
Prophylactic use of oral antistaphylococcal antibiotic
Scheduled antibiotics every 3-4 months / symptom-based treatment